Hybrid Pharmaceutical, The Genomics Biotech Engineering Company, announced Barron Graham’s –Join Hybrid GenNxeix Inc as Chief Information Officer

Houston, TX – November 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceutical, the Genomics Biotech Engineering company, today announced that Barron Graham’s – Graham is to join Hybrid GenNxeix Inc. (GenNxeix) as a Biotech Consulting Partner effective November 1, 2011. Barron will work directly with the Vice President of Worldwide Marketing in developing strategic marketing, branding, communications and sales initiatives for Hybrid GenNxeix ®. Mr. Graham bring more than 28years of expertise in brand management, business planning, advertising, digital, integrated communications, direct marketing, promotions, research and sales & marketing.

Barron brings a breath of experience and strong track record of leadership in successfully building brands and pioneering new markets,” said Rose Conrad Ph.D., Chief Executive Officer of Hybrid Pharmaceutical.
“His years of experience in developing go-to-market strategies, his intelligence and his excitement to become part of Hybrid GenNxeix is evident that Barron’s direction and steward of the GenNxeix brand will help to strengthen and solidify our market leadership position,” she said.



Hybrid GenNxeix a new subsidiary of Hybrid Pharma, is committed to being the world’s premiere Medical Informatics and Medical Services Companies. As a leader in genomic trials, healthcare IT, scientist electronic GenNxeix, development and manufacturing of biologics, the company offers a suite of products and services. Products and services include DNA paternity testing, Genomics analysis and testing, BioGenetic research and samples and Regenerative medicine.

As an entrepreneur for more than 28 years, Barron Graham’s unique qualifications in Business Establishment, Business Development and Marketing makes him highly capable and much sought after in the business world. His experience and expertise came from across section of industries namely: Real Estate, Investment Banking, Telecoms Retail, Business Financing, Insurance, Merchant Services, Network Marketing and Business Establishment & Development. In which he is personally starting more than 100 companies in several countries.


This press release contains forward-looking statements, including statements relating to the expected demand for Hybrid Pharma's products and services, statements regarding Hybrid Pharma’s growth and market opportunities, and statements relating to Hybrid Pharma’s ability to meet the needs of distributed organizations. These forward-looking statements involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Hybrid Pharma reserves the right to modify future product plans at any time.
About Hybrid Pharma

Hybrid Pharma is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services is available at GenNxeix.

“As you look around, you’ll see that medicine has changed dramatically. There is a huge Genomic shift occurring. The Genomicst has completely redefined the world’s economy and has created evidence base Medicine. If you are in medicine today and you are not using Genomics Science o, you will be left behind.”

20% Of Breast Cancers IS HER2 over-expressed. HER2 Gene Amplified Has A 82% Chance of Relapses

Robert Graham and Hybrid Medical Media Reporting from University of Texas Houston October, 2011-------

20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.
science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.

The better News is that Genomics is on the Clock.


Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect
the Her2 gene by using Semiconductor Sequencing. A example of
this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA ohttp://www.blogger.com/img/blank.gifr RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.